Vidac Pharma Holding (STU:T9G) Receivables Turnover : 0.00 (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Vidac Pharma Holding Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Vidac Pharma Holding's Revenue for the six months ended in Jun. 2024 was €0.00 Mil. Vidac Pharma Holding's average Accounts Receivable for the six months ended in Jun. 2024 was €0.03 Mil.

Vidac Pharma Holding Receivables Turnover Historical Data

The historical data trend for Vidac Pharma Holding's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vidac Pharma Holding Receivables Turnover Chart

Vidac Pharma Holding Annual Data

Trend

Dec21

Dec22

Dec23

Receivables Turnover

Vidac Pharma Holding Semi-Annual Data
	Jun22	Dec22	Jun23	Dec23	Jun24
Receivables Turnover	-	-	-	-	-

Competitive Comparison of Vidac Pharma Holding's Receivables Turnover

For the Biotechnology subindustry, Vidac Pharma Holding's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vidac Pharma Holding's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vidac Pharma Holding's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Vidac Pharma Holding's Receivables Turnover falls into.

Vidac Pharma Holding Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Vidac Pharma Holding's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	0	/ (	(0.009	+	0.063)	/	2 )
=	0	/	0.036
=	N/A

Vidac Pharma Holding's Receivables Turnover for the quarter that ended in Jun. 2024 is calculated as

	Receivables Turnover (Q: Jun. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Jun. 2024 )	/ (	(Accounts Receivable (Q: Dec. 2023 )	+	Accounts Receivable (Q: Jun. 2024 ))	/	count )
=	0	/ (	(0.063	+	0.002)	/	2 )
=	0	/	0.0325
=	N/A

Vidac Pharma Holding (STU:T9G) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Vidac Pharma Holding Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Vidac Pharma Holding's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Vidac Pharma Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vidac Pharma Holding PLC (STU:T9G) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

Wenlock Road, 20-22, London, GBR, N1 7GU

Website

https://www.vidacpharma.com

Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company developing first-in-class oncologic and onco-dermatologic therapies. Its drug, VDA-1102, is at the clinical development stage as an ointment for patients with actinic keratosis, an early form of skin cancer, and in a separate trial for an indication of cutaneous T-cell lymphoma (CTCL). A second molecule, VDA-1275, with possible application for a wide range of solid tumors.

Vidac Pharma Holding Headlines

No Headlines